These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3434974)

  • 1. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemical synthesis of dual-radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells.
    White DA; Heffron F; Miciak A; Middleton B; Knights S; Knight D
    Xenobiotica; 1990 Jan; 20(1):71-9. PubMed ID: 2327109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate.
    Middleton B; Middleton A; Miciak A; White DA; Bell GD
    Biochem Pharmacol; 1983 Feb; 32(4):649-51. PubMed ID: 6681959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the bioavailability of cyclandelate from commercial capsules.
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Takahashi T; Uezono Y; Imazato Y
    Clin Pharmacol Ther; 1991 Jun; 49(6):641-7. PubMed ID: 2060253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 9. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of cyclandelate on cholesterol synthesis.
    Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
    Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
    [No Abstract]   [Full Text] [Related]  

  • 11. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo inhibition of hepatic lipogenesis in the rat by cyclandelate (3,3',5-trimethylcyclohexanylmandelate).
    Middleton A; White DA; Bell GD; Middleton B
    Biochem Pharmacol; 1983 Oct; 32(20):3079-83. PubMed ID: 6639676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of a product of esterification of mandelic acid with 3,5,5-triethylcyclohexanol (cyclospasmol) in the treatment of peripheral arteriopathy].
    STARACE G; NOFERI A; PADULA R
    Gazz Med Ital; 1960 Apr; 119():133-6. PubMed ID: 13833815
    [No Abstract]   [Full Text] [Related]  

  • 15. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of atherosclerosis in the rabbit by cyclandelate.
    Middleton A; Edwards E; White DA; Middleton B
    Br J Clin Pract Suppl; 1984; 34():39-42. PubMed ID: 6430322
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution of tritiated cyclandelate (3,5,5-trimethylcyclohexyl mandelate)-a vasoactive drug: preliminary observations by liquid scintillation spectrometry.
    Orr A; Whittier JR
    Int J Nucl Med Biol; 1974 Jun; 1(4):205-13. PubMed ID: 4435997
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.